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Previewsbacteria with engaged TLR4 or both. The
report by the authors that their cells lack-
ing Rab11a have no defects in phagocy-
tosis supports their model, but it is also
counter to much previous literature on
the role of recycling endosomes in
controlling the very formation of phago-
somes (Bajno et al., 2000; Cox et al.,
2000). Future studies will need to be per-
formed to definitively implicate this novel
route of transport. Despite this potential
caveat, it is clear that Rab11a regulates
TLR4 transport in several cell types and
thus plays an important role in controlling
LPS-induced signal transduction.
As with any provocative study, several
questions arise. What is the signal that
originates from phagosomes that induce
the recruitment of recycling endosomes
to this bacterial containing compartment?
Do all cells that undergo TLR signaling
deliver TLR4 to phagosomes by the580 Immunity 33, October 29, 2010 ª2010 Elsame process? Is there any function for
the delivery of recycling endosomes to
phagosomes in terms of the control of
antigen presentation?
In summary, the study by Husebye et al.
adds to the idea that pattern recognition
receptors have been integrated in a well-
oiled cell biological machine, which
ensures rapid ignition of innate immune
signaling, and (we presume), rapid inacti-
vation of signaling when needed. Future
work will need to be done to build upon
this rapidly burgeoning field of innate
immune cell biology.REFERENCES
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The signaling pathway of the cytokine Flt3L in dendritic cells (DCs) is poorly defined. In this issue of Immunity,
Sathaliyawala et al. (2010) report that the kinasemTOR functions as amediator of Flt3L signaling in the devel-
opment and homeostasis of DCs, particularly of the CD8+ and CD103+ DCs.The fms-like thyrosine kinase 3 receptor
(Flt3) and its ligand (Flt3L) are key regula-
tors of dendritic cell (DC) commitment
and development. Flt3 is expressed
on the surface of early mutlipotent hea-
matopoietic progenitors, committed DC
precursors, and differentiated DC in
mouse lymphoid tissues. Flt3 expression
and its signaling has been shown to be
essential for steady-state DC develop-
ment and homeostasis as loss of Flt3 or
its ligand resulted in a substantial reduc-
tion in DC numbers in mouse lymphoid
tissues (Schmid et al., 2010). The ligand
for Flt3 can promote DC differentiationfrom both mouse and human hematopoi-
etic progenitors. Administration of Flt3L
induces marked expansion in numbers
of all DC subsets including the plasmacy-
toid DC (pDC) and both CD8+ and CD8
conventional DC (cDC) in mouse spleen,
albeit with a strong bias toward the
expansion of the CD8+ cDC subset
(Schmid et al., 2010). Flt3L-supplemented
bone marrow (BM) cultures support the
generation of pDCs and the two cDC
subsets phenotypically and functionally
equivalent to those identified in mouse
spleen (Naik et al., 2005). Despite the
importance of Flt3 and its ligand in DCdevelopment, the signaling pathway
downstream of Flt3 in DC differentiation
and homeostasis remains poorly charac-
terized.
The mammalian target of rapamycin
(mTOR) is a serine-threonine kinase that
acts as a central regulator for protein
synthesis and cell growth. mTOR activa-
tion is induced by PI3K-Akt signaling
pathway upon receptor binding to cyto-
kine or growth factors, which leads to
phosphorylation of ribosomal protein S6
that regulates ribosomal biogenesis,
protein translation, and cell growth
(Engelman et al., 2006). The PI3K-mTOR
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multiple roles in regulating both innate
and adaptive immunity. Within the DC
lineage, activation of mTOR can induce
the production of type-I IFN by pDCs but
suppress lipopolysacchride induced
interleukin-12 (IL-12) production by bone
marrow-derived cDCs (Weichhart and
Saemann, 2009). The activity of mTOR is
tightly regulated by several negative regu-
lators. Rapamycin, a bacterial protein, is
a specific inhibitor of mTOR signaling.
The phosphatase and tensin homolog
(Pten) is a key inhibitor of Akt signaling
that prevents Akt activation through de-
phosphorylating PI3K-generated inositol
phospholipids. Deletion of Pten results in
constitutive activation of PI3K-Akt
signaling. Although the roles of mTOR in
regulating DC functions have been
demonstrated, it is not clear whether
mTOR signaling also plays a role in DC
development. The link between Flt3 and
mTOR signaling has been suggested in
acute myeloid leukemia (AML) in which
Flt3 mutations result in ligand-indepen-
dent activation of the receptor and its
downstream signaling pathways
including the PI3K-mTOR pathway (Stire-
walt and Radich, 2003). However, the
potential role of Flt3L-induced PI3K-
AKT-mTOR signaling in normal hemato-
poietic cell development, particularly in
DC development, has not been clearly
defined.
In this issue of Immunity, Sathaliyawala
et al. (2010) examined the role of mTOR
signaling in Flt3L-induced DC develop-
ment and demonstrated that mTOR can
act as a mediator of Flt3L signaling in DC
development and homeostasis. Using
the Flt3L-supplemented BM cultures that
generate pDCs and the CD11bhiCD24lo
and CD11bloCD24hi cDCs, equivalent to
the CD8 and CD8+ cDC subsets found
in mouse spleen, respectively (Naik et al.,
2005), Sathaliyawala et al. (2010) found
that addition of rapamycin into these
cultures markedly reduced the number of
all DC subsets generated and the pDCs
and CD11bloCD24hi cDCs appeared to
be more sensitive to rapamycin treatment
than theCD11bhiCD24lo cDCs. Analysis of
CFSE-labeledBM inday3Flt3L cultures in
the presence of rapamycin revealed
a marked reduction in the numbers of
proliferating DC progenitors. In contrast,
addition of rapamycin did not affect DC
development in GM-CSF-supplementedBM cultures, suggesting a specific role of
mTOR signaling in Flt3L-induced DC
development. Measurement of phosphor-
ylated S6 (p-S6) as a readout of mTOR
signaling after injection of Flt3L revealed
a robust p-S6 signal in splenic DCs,
confirming that Flt3L could induce
mTOR signaling in DCs in vivo. Moreover,
Flt3L-induced p-S6 signal was found to
be higher and more sustained in splenic
CD8+ than CD8 cDCs, indicating a
higher activity of mTOR in CD8+ cDCs
thatmaypartially account for thepreferen-
tial expansion of CD8+ cDC numbers by
Flt3L.
Deletion of Pten causes hyperactivation
of PI3K-Akt pathway. For further testing of
the effects of PI3K-mTOR signaling in DC
development, Pten-deleted adult BM
were subjected into Flt3L cultures. An
accelerated and marked increase in the
development of CD11bloCD24hi cDC
was observed in these cultures. Further-
more, Pten deletion partially reversed
the inhibition of DC development by rapa-
mycin. Again, GM-CSF-induced DC
development was not affected by Pten
deletion, indicating a specific role of
PI3K-mTOR signaling in Flt3L-induced
DCdevelopment. Analysis of BMchimeric
mice established with BM from mice with
either global Pten deletion or DC-specific
Pten deletion showed similar strong
biased expansion of splenic CD8+ cDC
numbers, whereas the numbers of CD8
cDCs and pDCs were not affected. The
expansion of CD8+ cDC numbers in these
mice could be reversed to almost normal
amounts by administration of rapamycin,
confirming the requirement of mTOR
activation in the expansion of Pten-
deleted CD8+ cDC numbers. In addition,
by using the Cx3cr1-EGFP reporter
mice, Sathaliyawala et al. (2010) con-
firmed that the expansion of CD8+ cDC
numbers in Pten-deleted mice is mainly
within the Cx3cr1-EGFPCD8+ subset
but not the recently identified Cx3cr1-
EGFP+CD8+ cDCs, the development of
latter is Flt3 independent (Bar-On et al.,
2010).
In nonlymphoid tissues, the CD103+ DC
have been shown to have similar func-
tional capacities and developmental
origin to that of CD8+ cDCs in lymphoid
tissues. The development of these tissue
CD103+ DCs is also dependent on Flt3L
signaling (del Rio et al., 2010). In line
with this, increased number of theImmunity 33CD103+CD11b cDCs was also observed
in various tissues of the Pten-deleted
mice, again demonstrating a regulatory
role of Pten in PI3K-mTOR signaling in
Flt3L-induced DC development.
The maintenance of DC subset homeo-
stasis is important for a balanced
immune system and for efficient protec-
tive immune responses against certain
pathogens. Sathaliyawala et al. (2010)
showed that the imbalanced expansion
of CD8+ cDC in Pten-deleted mice is
detrimental. An impaired immunity to
the intracellular bacteria Listeria was
observed in Pten-deleted mice. This
could be partially due to the immaturity
of Flt3L expanded DCs. It is also possible
that the increased number of DCs served
as a reservoir for intracellular bacterial
replication.
The transcription factor Stat3 has been
reported as an essential factor for Flt3L-
dependent DC development (Laouar
et al., 2003). Loss of Stat3 activity
completely blocked Flt3L-induced devel-
opment of all DC subsets in lymphoid
tissues. It is not clear whether Stat3 is
involved in PI3k-mTOR-mediated Flt3L
signaling as described by Sathaliyawala
et al. (2010). It has been suggested that
Stat3 activity can be regulated by mTOR
pathway in immune cells. Further investi-
gation is required to define the molecular
events downstream of mTOR signaling.
The fact that Flt3L administration in vivo
induced marked expansion of all DC
subsets, albeit with greater extent in
CD8+ cDCs in normal mice, whereas
Pten deletion only caused expansion of
CD8+ cDCs in vivo, suggests that this
PIK3-mTOR pathway is mainly operating
in CD8+ cDCs or their precursors in vivo
and may represent an additional pathway
downstream of Flt3L signaling, which
parallels or synergizes with Flt3L-Stat3
pathway in the development or expansion
of CD8+ cDC numbers (Figure 1).
The importance of mTOR in regulating
human DC differentiation and functions
has also been recognized. A recent study
demonstrated a divergent role of mTOR
during activation and differentiation of
human myeloid DCs and monocyte-
derived DCs (Haidinger et al., 2010).
The human equivalent of mouse CD8+
cDC has also been identified by their
expression of BDCA-3 (CD141), CLEC9A
(a C-type lectin-like receptor), and XCR1
(a chemokine receptor) and their capacity, October 29, 2010 ª2010 Elsevier Inc. 581
Figure 1. mTOR Mediates Flt3L Signaling in Dendritic Cell Development and Homeostasis
Binding of Flt3L to its receptor expressed on the surface of DC precursors or DC induces activation of its
downstream PI3K-Akt-mTOR signaling pathway that leads to DC differentiation and expansion. The PI3K-
Akt-mTOR pathway can be suppressed by Pten, a key inhibitor of Akt signaling, and by rapamycin, the
specific inhibitor of mTOR, which leads to restrained DC development and expansion. Flt3L signaling
may directly activate Stat3 pathway and lead to DC development.
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Previewsto produce IL-12 and to cross-present
exogenous antigen. They can also be
generated in culture in the presence of582 Immunity 33, October 29, 2010 ª2010 ElFlt3L. It is important to determine whether
the PI3K-mTOR pathway also functions in
a similar way during the development andsevier Inc.homeostasis of human BDCA-3+ cDCs.
These studies should provide important
information for the potential effects of ra-
pamycin treatment on the development
and functions of DCs in human patients
that is crucial for developing novel strate-
gies for improved therapeutic applica-
tions of rapamycin in the treatment of
various human diseases.REFERENCES
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